Introduction
4,10-dichloropyrido
thieno [3,2- [10] . Oral administration of DTD reduced the degree of granulomatous inflammation and vascular density in a murine air pouch granuloma model. The inhibition of the endogenous production of angiogenic cytokines and COX-2 expression in the granuloma, was then suggested to participate in the inhibition of vascularization by DTD in this model of inflammation [11] . [2,3-b] pyridines according to modified procedures from the literature [12] 
d':3,2-d]-1,2,3-ditriazine (DTD) (Fig.1), is a ditriazine derivative that modulates acute inflammation in murine models by inhibition of leukocyte functions and expression of nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2)

Results presented here show for the first time that the antiangiogenic effect of DTD is not only due to a putative modulation of the production of angiogenic cytokines in inflammation, but it is exerted directly on endothelial cells. DTD inhibits angiogenesis in vivo in a widely employed angiogenesis assay (chorioallantoic membrane assay). Furthermore, in vitro assays show that DTD interferes several functions of the activated endothelial cells, namely proliferation, proteases production and differentiation. Taken together, our data suggest the possibility of utilising this compound for the treatment of angiogenesis-related diseases.
Materials and methods
Materials
Cell culture media were purchased from Gibco (Grand Island, NY, USA) and Cambrex (Walkersville, MD, USA). Foetal bovine serum (FBS) was a product of Harlan-Seralab (Belton, U.K.). Matrigel was purchased from Becton Dickinson (Bedford, MA, USA). Supplements and other chemicals not listed in this section were obtained from Sigma Chemicals Co. (St. Louis, Mo., USA). Plastics for cell culture were supplied by NUNC (Roskilde, Denmark). DTD was prepared by diazotation of 3,6-diamino-2,5-dicyanothieno
Chorioallantoic membrane (CAM) assay
CAM assay was performed as described [16] . 
Conditioned media and gelatinograms
Results
DTD inhibits in vivo angiogenesis in the chick chorioallantoic membrane assay
The CAM assay is frequently used to determine the ability of test compounds to inhibit in vivo angiogenesis. In controls, blood vessels form a dense and spatially oriented branching network composed by vascular structures of progressively smaller diameter as they branch (Fig. 2A) . Table 1 Fig. 2B and C) . Signs of inflammation, such as a whitening of the CAM, were not observed. (Fig. 3A) (Fig. 3A) .
DTD inhibits the growth of endothelial and tumour cells
Angiogenesis involves local proliferation of endothelial cells. We investigated the ability of DTD to inhibit the growth of endothelial cells. Survival curves obtained with the MTT assay showed that DTD inhibited, in a concentration-dependent manner, the growth of cultured endothelial cells
DTD does not induce apoptosis in endothelial cells
As a first approach to determine whether DTD could induce apoptosis in endothelial cells, nuclear morphology and flow cytometric analysis of the cell sub-population distribution were investigated in BAE cells after 14 hrs treatment with 3 or 15 M of DTD. Our data show that neither significant changes on the nuclear morphology (Fig. 3B ) nor significant increases in sub-G1 population (Fig. 3C (Fig. 3C) . This pattern is consistent with blocks to progression at the S and G2/M phases of the cell cycle and may underlie the growth inhibitory activity observed for this compound. Fig. 3 (A angiogenesis. Taking into account the previously described downregulation of COX-2 expression levels by DTD in inflammatory cells [10, 11] , the effect of DTD on endothelial COX-2 expression was investigated. As shown in Fig. 6 [18] . Our results show that DTD inhibits the neovascularisation of the chick chorioallantoic membrane at concentrations that are several orders of magnitude lower than those required for other inhibitors of angiogenesis [19] [20] [21] , demonstrating that this compound exhibits a potent anti-angiogenic activity, independently of a putative [22, 23] . DTD is not a specific inhibitor or endothelial cell growth. This lack of specificity is also exhibited by other anti-angiogenic compounds that are considered to act mainly through inhibition of endothelial cell proliferation [23] . Although in our hands the anti-proliferative activity has not been the most prominent effect of DTD on endothelial cells, its contribution to the anti-angiogenic potential role of DTD can not be ruled out.
DTD inhibits the capillary chord formation by endothelial cells
The final event during angiogenesis is the organisation of endothelial cells in a three-dimensional network of tubes. In vitro, endothelial cells plated on Matrigel align themselves forming tubelike structures, already evident a few hours after plating (Fig. 4A and C) Figures 4B and 4D show that DTD was able to completely inhibit the BAE and HUVE cell alignment and chord formation. The minimal concentration of compound yielding a complete inhibition of endothelial morphogenesis on Matrigel was
CAM assay was carried out with different doses of DTD, as described in Material and methods. Data are given as percentage of eggs with inhibited angiogenesis in their CAMs per total number of treated egg CAMs
M for BAE and 3.0 M for HUVE cells. The concentrations required to inhibit the differentiation of BAE and HUVE cells, did not affect their viability after 7 hrs (results not shown).
Effect of DTD on endothelial and tumour cells gelatinases secretion
Angiogenesis involves the acquisition by endothelial cells of the capability to degrade the basement membrane and, in general, to remodel the extracellular matrix. As shown in Fig. 5, in our hands HUVE cells express the 72 kD pro-form of MMP-2. However, no MMP-9 secretion by HUVEC could be detected. Gelatin zymography of conditioned media of HUVE cells untreated and treated for 24 hrs with 3 or 15 M of DTD (Fig. 5), shows that 15 M of this compound produced complete inhibition of MMP-2 secretion by endothelial cells. The effect on MMP-2 production does not seem to be endothelial-specific, since a decrease in MMP-2 secretion by HT1080 tumour cells was also observed after treatment with 15 M DTD. No effect on MMP-9 levels was observed after HT1080 treatment with 15 M DTD (Fig. 5).
Effect of DTD on endothelial COX-2 expression
Inhibition of either endothelial COX-2 expression or of its enzymatic activity has recently been considered a new strategy to inhibit
Discussion
The new ditriazine derivative DTD exerts anti-inflammatory effects related to the inhibition of neutrophil functions and of NO and prostaglandin E2 (PGE2) production, which could be due to a decreased expression of inducible NO synthase and COX-2 in activated macrophages [10]. DTD inhibits the vascularisation in an inflammatory model, what has been suggested to be related to inhibition of cytokine and PGE2 production by interfering with NF-B activation [11]. The objective of our work has been to determine if DTD could inhibit angiogenesis in vivo in a model where inflammation was not directly involved, and to elucidate if DTD might directly interfere any of the following key steps mediated by endothelial cells: degradation of the basement membrane, proliferation of endothelial cells, and the formation of capillary-like chords. The evaluation of the potential anti-angiogenic activity of test compounds in the in vivo CAM assay is one of the most widely used in vivo angiogenesis assays
Our data indicate that DTD inhibits capillary-like chord formation by endothelial cells at concentrations that are lower than or in the same range as those required for other previously described inhibitors of angiogenesis [19-21, 24, 25] . The concentrations required for a complete abrogation of tubulogenesis were lower than those required to inhibit cell proliferation, and do not affect human neutrophils or murine macrophages viability [10, 11] [3, 4] .
A positive proteolytic balance is required for capillary sprouting and lumen formation during angiogenesis. Matrix metalloproteinases, particularly the gelatinases MMP-2 and MMP-9, play a central role during angiogenesis [27] . Endothelial cells constitutively secrete MMP-2, which is required for the tumour to trigger the angiogenic response [28] . MMP-2 is secreted as an 72 kD inactive pro-form; when it is converted to a 62 kD active form it can degrade collagen types IV and V, laminin and elastin. In intact cells, MMP-2 is activated at the cell surface by a process involving interaction of the C-terminal component of MMP-2 with a plasma membrane activation mechanism [27] . Our data show that incubation with DTD inhibits MMP-2 proform secretion by HUVE cells. Similar decreases of pro-MMP-2 levels in the conditioned media of endothelial cells have been described for halofuginone [29] and aeroplysinin-1 [24] [33] . Therefore, the targeting of endothelial COX-2, either by inhibiting its enzymatic activity or by blocking its transcription, might be useful in combating angiogenesis-dependent diseases [34] . Previous results showing that DTD inhibited the COX-2 expression by lipopolysaccharide-stimulated murine peritoneal macrophages in vitro [10] and that a decreased COX-2 expression was observed in murine air pouch granuloma after oral administration of DTD [11] 
